The companies will use Sangamo’s proprietary zinc finger protein (ZFP) technology delivered via adeno-associated virus to change the expression of genes involved in these diseases. Biogen will ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback